| Subject: | FDA Issues Public Health Advisory About "Off Label" Use of Antipsychotic Drugs |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 15 Apr 2005 - 10:00 am |
| The FDA has issued a Public Health Advisory about the dangers of unapproved (off label) use of certain antipsychotic medications which are approved for use in treating schizophrenia, prescribed off label for the use of behavioral disorders in elderly patients with dementia. The FDA states that there is an association of increased mortality with the treatment of elderly dementia patients with atypical antipsychotic (second generation) medications. The FDA cites seventeen placebo-controlled... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. Other vendors have components of legislated requirements available online or on CD-ROM. However there is no other product that marries regulatory agency mandates with implementation tools, making the latest compliance information immediately available online. No other product provides an interpretative analysis, followed by a practical application tool, therefore providing users with an immediate solution to compliance problems. StayAlert! includes operational components for healthcare organizations, allowing complete facility compliance with mandated requirements, online. |
|
